The usage of cannabidiol ( CBD) for therapy of pharmacoresistant epilepsies is rising. CBD is metabolized through UDP-glucuronosyltransferase (UGT) and cytochrome 450 (CYP) enzymes, however info on interactions with widespread anticonvulsive medicine is incomplete. We report a case collection of 5 sufferers receiving adjunctive therapy with CBD who confirmed will increase in brivaracetam (BRV) ranges by 95% to 280%. Solely two sufferers reported gentle hostile occasions, resulting in a discount of BRV in a single affected person. One doable mechanism contributing at the least partially to rising BRV degree is the inhibition of CYP2C19 by cannabidiol. Additional pharmacokinetic research are required to grasp different doable mechanisms of brivaracetam-cannabidiol interplay.